BACKGROUND Even a single additional stroke risk factor in patients with atrial fibrillation may confer a risk of stroke.
A trial fibrillation (AF) confers a risk of strokes, which is associated with high mortality and disability. The risk of stroke is reduced by oral anticoagulation therapy, which, in historical trials using vitamin K antagonists (VKAs) such as warfarin, significantly reduced stroke/ systemic embolism by 64% and all-cause mortality by 26% (1) . The effect size of VKA is probably underestimated because many strokes in VKA-treated patients occurred while off therapy or during subtherapeutic anticoagulation. In contrast, aspirin reduces stroke by a nonsignificant 19%, with no impact on mortality (1) .
Although AF increases stroke risk 5-fold, this risk is not homogeneous and depends on additional stroke risk factors (2, 3) . In addition, the landscape for stroke prevention in AF has changed with the recognition of the need for well-managed VKA (with average time-in-therapeutic-range >65% to 70%) (4, 5) and the recent availability of the non- i.e., a CHA 2 DS 2 -VASc [congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category] score of 0 for male patients, 1 for female patients) who do not need any antithrombotic therapy (7) . Patients with $1 additional stroke risk factor can subsequently be offered stroke prevention with oral anticoagulation. The 2014 National Institute for Health and Care Excellence (NICE) guidelines recommend a similar approach, and aspirin is not recommended (8) .
However, the 2014 American Heart Association/ American College of Cardiology/Heart Rhythm Society guidelines recommend oral anticoagulation for patients with a CHA 2 DS 2 -VASc score $2 and no therapy for those with a CHA 2 DS 2 -VASc score of 0; for patients with a CHA 2 DS 2 -VASc score of 1, no therapy, aspirin, or oral anticoagulation is recommended (9) .
Given that even a single risk factor in patients with Illustrates patient selection for analyses. AF ¼ atrial fibrillation.
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Lip et al. Table 3 ).
Bleeding event rates among untreated low-risk patients (CHA 2 DS 2 -VASc scores of 0 [male] or 1
[female]) were low (1.08 per 100 person-years at 1 year and 0.97 at full follow-up with an ITT approach).
For patients who initiated warfarin treatment, the Values are n (%), median (interquartile range), or mean AE SD.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; ARB ¼ angiotensin receptor blocker; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/ transient ischemic attack, vascular disease, age 65 to 74 years, sex category; CHF ¼ congestive heart failure; CT ¼ continuous treatment; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (>65 years), drugs/alcohol concomitantly; ITT ¼ intention-to-treat; LVD ¼ left ventricular dysfunction; NSAID ¼ nonsteroidal anti-inflammatory drugs.
corresponding rates were 1.66 and 1.42 ( Table 2) . With additional risk factors, there was a corresponding increase in event rates, with rates at 1 year of 2.42 and at full follow-up of 2.32 for warfarin-treated patients.
Similar trends were seen with a CT approach. One-year intracranial hemorrhage event rates among patients with 1 risk factor were w0.4 for untreated patients and slightly higher for warfarin-treated patients.
Death rates with no risk factors for untreated patients were w3.9 and were much higher for the group of older patients in the group with 1 risk factor. Lip et al. Detailed adjusted analysis of the stroke endpoints in Online Table 5 
NOAC or good-quality anticoagulation international
normalized ratio control with a VKA (time-intherapeutic range >70%), which offers the best efficacy and safety when VKAs are used (4, 5) . Indeed, given the availability of NOACs, the threshold for treatment may be a stroke rate of 0.9% per year (16).
It has previously been shown that stroke rates could be as high as 8.1% among patients with a single risk factor (using the older CHADS 2 score [congestive heart failure, hypertension, age $75 years, diabetes mellitus age 65 to 74 years (10) . Even among patients unsuited for warfarin treatment, in whom the common practice previously was to offer aspirin, the oral factor Xa inhibitor apixaban was superior to aspirin for stroke prevention, with a similar rate of major bleeding and intracranial hemorrhage (18) . Of note, other guidelines (19, 20) , including the previous U.S. guidelines (21) (e.g., time-in-therapeutic range). We recognize that treatment adherence/discontinuation is an important consideration for patient management (27) , but a thorough analysis is beyond the scope of this paper, which addresses the question of whether CHA 2 DS 2 -VASc would be best managed with "nothing, aspirin, or warfarin" on the basis of "real-world" observational data. Lip et al.
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